Brokers Suggest Investing in Teradyne (TER): Read This Before Placing a Bet

10.04.25 15:30 Uhr

Werte in diesem Artikel
Aktien

67,16 EUR -1,64 EUR -2,38%

Indizes

10.210,8 PKT -98,3 PKT -0,95%

5.921,5 PKT 118,7 PKT 2,05%

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Let's take a look at what these Wall Street heavyweights have to say about Teradyne (TER) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Teradyne currently has an average brokerage recommendation (ABR) of 1.73, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 15 brokerage firms. An ABR of 1.73 approximates between Strong Buy and Buy.Of the 15 recommendations that derive the current ABR, 11 are Strong Buy, representing 73.3% of all recommendations.Brokerage Recommendation Trends for TERCheck price target & stock forecast for Teradyne here>>>While the ABR calls for buying Teradyne, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.Zacks Rank Should Not Be Confused With ABRAlthough both Zacks Rank and ABR are displayed in a range of 1-5, they are different measures altogether.The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.Is TER Worth Investing In?Looking at the earnings estimate revisions for Teradyne, the Zacks Consensus Estimate for the current year has declined 13% over the past month to $3.38.Analysts' growing pessimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates lower, could be a legitimate reason for the stock to plunge in the near term.The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #5 (Strong Sell) for Teradyne. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Therefore, it could be wise to take the Buy-equivalent ABR for Teradyne with a grain of salt.7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Teradyne, Inc. (TER): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Teradyne und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Teradyne

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Teradyne

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Teradyne Inc.

Wer­bung

Analysen zu Teradyne Inc.

DatumRatingAnalyst
25.04.2019Teradyne Market PerformCowen and Company, LLC
25.10.2018Teradyne BuyCraig Hallum
26.07.2018Teradyne BuyNeedham & Company, LLC
26.07.2018Teradyne Market PerformCowen and Company, LLC
26.01.2018Teradyne BuyNeedham & Company, LLC
DatumRatingAnalyst
25.10.2018Teradyne BuyCraig Hallum
26.07.2018Teradyne BuyNeedham & Company, LLC
26.01.2018Teradyne BuyNeedham & Company, LLC
24.01.2018Teradyne BuyStifel, Nicolaus & Co., Inc.
05.07.2017Teradyne BuyStifel, Nicolaus & Co., Inc.
DatumRatingAnalyst
25.04.2019Teradyne Market PerformCowen and Company, LLC
26.07.2018Teradyne Market PerformCowen and Company, LLC
21.11.2017Teradyne HoldDeutsche Bank AG
29.10.2015Teradyne Sector WeightPacific Crest Securities Inc.
11.06.2012Teradyne neutralUBS AG
DatumRatingAnalyst
30.07.2009Teradyne ErsteinschätzungMorgan Stanley
22.12.2008Teradyne underweightJP Morgan Chase & Co.
06.12.2005Update Teradyne Inc.: UnderperformGoldman Sachs
06.12.2005Teradyne underperformGoldman Sachs

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Teradyne Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen